PAE ameliorates doxorubicin-induced cardiotoxicity via suppressing NHE1 phosphorylation and stimulating PI3K/AKT phosphorylation

Yaling Yin,Qianqian Niu,Hongyan Hou,Huadong Que,Shan Mi,Jinfang Yang,Zitian Li,Huanhuan Wang,Yanan Yu,Moli Zhu,Heqin Zhan,Qianqian Wang,Peng Li
DOI: https://doi.org/10.1016/j.intimp.2022.109274
IF: 5.714
2022-12-01
International Immunopharmacology
Abstract:Doxorubicin (DOX), a broad-spectrum anti-tumor drug, has severe cardiotoxic side effects that limit its clinical application. Perillaldehyde (PAE) is the main component of volatile oil extracted from the stems and leaves of Herbaceous plant-perilla, which demonstrates antioxidant, anti-inflammatory, hypolipidemic, and other health functions. The present study aimed to explore the protective effect of perillaldehyde on DOX-induced cardiotoxicity in rats and to confirm its possible mechanism. The results showed that PAE could significantly improve cardiac function, alleviate myocardial fibrosis, and attenuate oxidative stress and inflammatory responses in DOX-induced cardiotoxicity in rats. Mechanistically, PAE could DOX-induced cardiotoxicity, which is related to its regulation of the PI3K/Akt signaling pathway and inhibition of NHE1 phosphorylation. Therefore, the finding demonstrates that perillaldehyde may be a promising cardioprotective agent for the prevention and treatment of cardiotoxicity caused by DOX.
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?